Endocyte Overview

  • Year Founded
  • 1995

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 44

Employees

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 11

  • Investments
  • 1

Endocyte General Information

Description

Developer of receptor-targeted therapeutics for the treatment of cancer and autoimmune diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug.

Contact Information

Website
www.endocyte.com
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 3000 Kent Avenue
  • Suite A1-100
  • West Lafayette, IN 47906
  • United States
+1 (765)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 3000 Kent Avenue
  • Suite A1-100
  • West Lafayette, IN 47906
  • United States
+1 (765)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Endocyte Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Endocyte‘s full profile, request access.

Request a free trial

Endocyte Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of receptor-targeted therapeutics for the treatment of cancer and autoimmune diseases. The company provides EC
Drug Discovery
West Lafayette, IN
44 As of 2017

Bothell, WA
 

Alameda, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Endocyte Competitors (57)

One of Endocyte’s 57 competitors is Seagen, a Formerly VC-backed company based in Bothell, WA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Seagen Formerly VC-backed Bothell, WA
Exelixis Formerly VC-backed Alameda, CA
Apexian Pharmaceuticals Venture Capital-Backed Indianapolis, IN
XBiotech Corporation Austin, TX
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
You’re viewing 5 of 57 competitors. Get the full list »

Endocyte Patents

  • 679

    Total Documents Applications and Grants

  • Total Patents Families

  • 219

    Granted

  • 87

    Pending

  • Expiring in next 12 mo

Endocyte Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2021242752-A1 Methods of controlling acute inflammatory response Inactive 26-May-2020
JP-2020117509-A Conjugates for treating diseases Pending 12-Mar-2020
EP-4107279-A1 Method of treating psma-expressing cancers Pending 18-Feb-2020
EP-4107279-A4 Method of treating psma-expressing cancers Pending 18-Feb-2020
US-20230098279-A1 Method of treating psma-expressing cancers Inactive 18-Feb-2020 A61P35/00
To view Endocyte’s complete patent history, request access »

Endocyte Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Endocyte Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Endocyte‘s full profile, request access.

Request a free trial

Endocyte Investments (1)

Endocyte’s most recent deal was a Corporate Asset Purchase with ABX Advanced Biochemical Compounds (177Lu-PSMA-617 Prostate Cancer Candidate ) for . The deal was made on 02-Oct-2017.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
ABX Advanced Biochemical Compounds (177Lu-PSMA-617 Prostate Cancer Candidate ) 02-Oct-2017 Corporate Asset Purchase Buildings and Property
To view Endocyte’s complete investments history, request access »

Endocyte FAQs

  • When was Endocyte founded?

    Endocyte was founded in 1995.

  • Where is Endocyte headquartered?

    Endocyte is headquartered in West Lafayette, IN.

  • What is the size of Endocyte?

    Endocyte has 44 total employees.

  • What industry is Endocyte in?

    Endocyte’s primary industry is Drug Discovery.

  • Is Endocyte a private or public company?

    Endocyte is a Private company.

  • What is the current valuation of Endocyte?

    The current valuation of Endocyte is .

  • What is Endocyte’s current revenue?

    The current revenue for Endocyte is .

  • How much funding has Endocyte raised over time?

    Endocyte has raised $172M.

  • Who are Endocyte’s investors?

    American Bailey Ventures, Blue Chip Venture Company, Burrill & Co, CHV Capital, and CID Equity are 5 of 12 investors who have invested in Endocyte.

  • Who are Endocyte’s competitors?

    Seagen, Exelixis, Apexian Pharmaceuticals, XBiotech, and Inovio Pharmaceuticals are some of the 57 competitors of Endocyte.

  • When was Endocyte acquired?

    Endocyte was acquired on 21-Dec-2018.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process